Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies

Current Opinion in Immunology

Volumn 42, Issue , 2016, Pages 56-64

  Wu, Xueling ^a   Kong, Xiang Peng ^b  

^a AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIBODY; EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HYBRID PROTEIN; MONOMER; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ANTIBODY COMBINING SITE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; B LYMPHOCYTE; COMPLEMENTARITY DETERMINING REGION; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; GERMINAL CENTER; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; REVIEW; SOMATIC HYPERMUTATION; VDJ RECOMBINATION; VIRUS ENTRY; VIRUS ENVELOPE; ANIMAL; ANTIGENIC VARIATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PRIMATE; VACCINE IMMUNOGENICITY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENIC VARIATION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGENICITY, VACCINE; PRIMATES; SOMATIC HYPERMUTATION, IMMUNOGLOBULIN;

EID: 84973307903     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.05.013     Document Type: Review

References (94)

1. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., Zhou T., Schmidt S.D., Wu L., Xu L., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
2. Scheid J.F., Mouquet H., Ueberheide B., Diskin R., Klein F., Oliveira T.Y., Pietzsch J., Fenyo D., Abadir A., Velinzon K., et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333:1633-1637.
3. Scharf L., Scheid J.F., Lee J.H., West A.P., Chen C., Gao H., Gnanapragasam P.N., Mares R., Seaman M.S., Ward A.B., et al. Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. Cell Rep 2014, 7:785-795.
4. Wu X., Zhou T., Zhu J., Zhang B., Georgiev I., Wang C., Chen X., Longo N.S., Louder M., McKee K., et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333:1593-1602.
5. Klein F., Gaebler C., Mouquet H., Sather D.N., Lehmann C., Scheid J.F., Kraft Z., Liu Y., Pietzsch J., Hurley A., et al. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J Exp Med 2012, 209:1469-1479.
6. Zhou T., Zhu J., Wu X., Moquin S., Zhang B., Acharya P., Georgiev I.S., Altae-Tran H.R., Chuang G.Y., Joyce M.G., et al. Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. Immunity 2013, 39:245-258.
7. Georgiev I.S., Doria-Rose N.A., Zhou T., Kwon Y.D., Staupe R.P., Moquin S., Chuang G.Y., Louder M.K., Schmidt S.D., Altae-Tran H.R., et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science 2013, 340:751-756.
8. Liao H.X., Lynch R., Zhou T., Gao F., Alam S.M., Boyd S.D., Fire A.Z., Roskin K.M., Schramm C.A., Zhang Z., et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013, 496:469-476.
9. Zhou T., Lynch R.M., Chen L., Acharya P., Wu X., Doria-Rose N.A., Joyce M.G., Lingwood D., Soto C., Bailer R.T., et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 2015, 161:1280-1292.
10. Freund N.T., Horwitz J.A., Nogueira L., Sievers S.A., Scharf L., Scheid J.F., Gazumyan A., Liu C., Velinzon K., Goldenthal A., et al. A new glycan-dependent CD4-binding site neutralizing antibody exerts pressure on HIV-1 in vivo. PLoS Pathog 2015, 11:e1005238.
11. Kong L., Ju B., Chen Y., He L., Ren L., Liu J., Hong K., Su B., Wang Z., Ozorowski G., et al. Key gp120 glycans pose roadblocks to the rapid development of VRC01-class antibodies in an HIV-1-infected Chinese donor. Immunity 2016, 44:939-950.
12. Kong R., Xu K., Zhou T., Acharya P., Lemmin T., Liu K., Ozorowski G., Soto C., Taft J.D., Bailer R.T., et al. Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody. Science 2016, 352:828-833.
13. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., Wrin T., Simek M.D., Fling S., Mitcham J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
14. Bonsignori M., Hwang K.K., Chen X., Tsao C.Y., Morris L., Gray E., Marshall D.J., Crump J.A., Kapiga S.H., Sam N.E., et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 2011, 85:9998-10009.
15. Walker L.M., Huber M., Doores K.J., Falkowska E., Pejchal R., Julien J.P., Wang S.K., Ramos A., Chan-Hui P.Y., Moyle M., et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477:466-470.
16. Pejchal R., Doores K.J., Walker L.M., Khayat R., Huang P.S., Wang S.K., Stanfield R.L., Julien J.P., Ramos A., Crispin M., et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 2011, 334:1097-1103.
17. Huang J., Ofek G., Laub L., Louder M.K., Doria-Rose N.A., Longo N.S., Imamichi H., Bailer R.T., Chakrabarti B., Sharma S.K., et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 2012, 491:406-412.
18. Doria-Rose N.A., Schramm C.A., Gorman J., Moore P.L., Bhiman J.N., DeKosky B.J., Ernandes M.J., Georgiev I.S., Kim H.J., Pancera M., et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014, 509:55-62.
19. Falkowska E., Le K.M., Ramos A., Doores K.J., Lee J.H., Blattner C., Ramirez A., Derking R., van Gils M.J., Liang C.H., et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 2014, 40:657-668.
20. Blattner C., Lee J.H., Sliepen K., Derking R., Falkowska E., de la Pena A.T., Cupo A., Julien J.P., van Gils M., Lee P.S., et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity 2014, 40:669-680.
21. Huang J., Kang B.H., Pancera M., Lee J.H., Tong T., Feng Y., Imamichi H., Georgiev I.S., Chuang G.Y., Druz A., et al. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature 2014, 515:138-142.
22. Gao F., Bonsignori M., Liao H.X., Kumar A., Xia S.M., Lu X., Cai F., Hwang K.K., Song H., Zhou T., et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 2014, 158:481-491.
23. Bonsignori M., Zhou T., Sheng Z., Chen L., Gao F., Joyce M.G., Ozorowski G., Chuang G.Y., Schramm C.A., Wiehe K., et al. Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. Cell 2016, 165:449-463.
24. Corti D., Langedijk J.P., Hinz A., Seaman M.S., Vanzetta F., Fernandez-Rodriguez B.M., Silacci C., Pinna D., Jarrossay D., Balla-Jhagjhoorsingh S., et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One 2010, 5:e8805.
25. Kwong P.D., Mascola J.R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012, 37:412-425.
26. Burton D.R., Ahmed R., Barouch D.H., Butera S.T., Crotty S., Godzik A., Kaufmann D.E., McElrath M.J., Nussenzweig M.C., Pulendran B., et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012, 12:396-407.
27. Burton D.R., Poignard P., Stanfield R.L., Wilson I.A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012, 337:183-186.
28. Haynes B.F., McElrath M.J. Progress in HIV-1 vaccine development. Curr Opin HIV AIDS 2013, 8:326-332.
29. Burton D.R., Mascola J.R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol 2015, 16:571-576.
30. Haynes B.F., Shaw G.M., Korber B., Kelsoe G., Sodroski J., Hahn B.H., Borrow P., McMichael A.J. HIV-host interactions: implications for vaccine design. Cell Host Microbe 2016, 19:292-303.
31. Sanders R.W., Derking R., Cupo A., Julien J.P., Yasmeen A., de Val N., Kim H.J., Blattner C., de la Pena A.T., Korzun J., et al. A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog 2013, 9:e1003618.
32. Julien J.P., Cupo A., Sok D., Stanfield R.L., Lyumkis D., Deller M.C., Klasse P.J., Burton D.R., Sanders R.W., Moore J.P., et al. Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science 2013, 342:1477-1483.
33. Pancera M., Zhou T., Druz A., Georgiev I.S., Soto C., Gorman J., Huang J., Acharya P., Chuang G.Y., Ofek G., et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514:455-461.
34. Kwon Y.D., Pancera M., Acharya P., Georgiev I.S., Crooks E.T., Gorman J., Joyce M.G., Guttman M., Ma X., Narpala S., et al. Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol 2015, 22:522-531.
35. Munro J.B., Gorman J., Ma X., Zhou Z., Arthos J., Burton D.R., Koff W.C., Courter J.R., Smith A.B., Kwong P.D., et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions. Science 2014, 346:759-763.
36. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M., Adams E., et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009, 361:2209-2220.
37. Haynes B.F., Gilbert P.B., McElrath M.J., Zolla-Pazner S., Tomaras G.D., Alam S.M., Evans D.T., Montefiori D.C., Karnasuta C., Sutthent R., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012, 366:1275-1286.
38. McLellan J.S., Pancera M., Carrico C., Gorman J., Julien J.P., Khayat R., Louder R., Pejchal R., Sastry M., Dai K., et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature 2011, 480:336-343.
39. Pancera M., Shahzad-Ul-Hussan S., Doria-Rose N.A., McLellan J.S., Bailer R.T., Dai K., Loesgen S., Louder M.K., Staupe R.P., Yang Y., et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol 2013, 20:804-813.
40. Pan R., Gorny M.K., Zolla-Pazner S., Kong X.P. The V1V2 region of HIV-1 gp120 forms a five-stranded beta barrel. J Virol 2015, 89:8003-8010.
41. Liao H.X., Bonsignori M., Alam S.M., McLellan J.S., Tomaras G.D., Moody M.A., Kozink D.M., Hwang K.K., Chen X., Tsao C.Y., et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013, 38:176-186.
42. Sok D., van Gils M.J., Pauthner M., Julien J.P., Saye-Francisco K.L., Hsueh J., Briney B., Lee J.H., Le K.M., Lee P.S., et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci U S A 2014, 111:17624-17629.
43. Kong L., Lee J.H., Doores K.J., Murin C.D., Julien J.P., McBride R., Liu Y., Marozsan A., Cupo A., Klasse P.J., et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol 2013, 20:796-803.
44. Zhou T., Zhu J., Yang Y., Gorman J., Ofek G., Srivatsan S., Druz A., Lees C.R., Lu G., Soto C., et al. Transplanting supersites of HIV-1 vulnerability. PLoS One 2014, 9:e99881.
45. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659.
46. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266:1024-1027.
47. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445:732-737.
48. West A.P., Diskin R., Nussenzweig M.C., Bjorkman P.J. Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. Proc Natl Acad Sci U S A 2012, 109:E2083-E2090.
49. Zhou T., Georgiev I., Wu X., Yang Z.Y., Dai K., Finzi A., Kwon Y.D., Scheid J.F., Shi W., Xu L., et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329:811-817.
50. Chen L., Kwon Y.D., Zhou T., Wu X., O'Dell S., Cavacini L., Hessell A.J., Pancera M., Tang M., Xu L., et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 2009, 326:1123-1127.
51. Wang Y., Sundling C., Wilson R., O'Dell S., Chen Y., Dai K., Phad G.E., Zhu J., Xiao Y., Mascola J.R., et al. High-resolution longitudinal study of HIV-1 Env vaccine-elicited B cell responses to the virus primary receptor binding site reveals affinity maturation and clonal persistence. J Immunol 2016, 196:3729-3743.
52. Scharf L., Wang H., Gao H., Chen S., McDowall A.W., Bjorkman P.J. Broadly neutralizing antibody 8ANC195 recognizes closed and open states of HIV-1 Env. Cell 2015, 162:1379-1390.
53. Lee J.H., Ozorowski G., Ward A.B. Cryo-EM structure of a native, fully glycosylated, cleaved HIV-1 envelope trimer. Science 2016, 351:1043-1048.
54. Buchacher A., Predl R., Strutzenberger K., Steinfellner W., Trkola A., Purtscher M., Gruber G., Tauer C., Steindl F., Jungbauer A., et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994, 10:359-369.
55. Purtscher M., Trkola A., Gruber G., Buchacher A., Predl R., Steindl F., Tauer C., Berger R., Barrett N., Jungbauer A., et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 1994, 10:1651-1658.
56. Stiegler G., Kunert R., Purtscher M., Wolbank S., Voglauer R., Steindl F., Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001, 17:1757-1765.
57. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001, 75:10892-10905.
58. Montero M., van Houten N.E., Wang X., Scott J.K. The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol Mol Biol Rev 2008, 72:54-84.
59. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004, 78:10724-10737.
60. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., Burton D.R., Wilson I.A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22:163-173.
61. Kim M., Sun Z.Y., Rand K.D., Shi X., Song L., Cheng Y., Fahmy A.F., Majumdar S., Ofek G., Yang Y., et al. Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization. Nat Struct Mol Biol 2011, 18:1235-1243.
62. Irimia A., Sarkar A., Stanfield R.L., Wilson I.A. Crystallographic identification of lipid as an integral component of the epitope of HIV broadly neutralizing antibody 4E10. Immunity 2016, 44:21-31.
63. Hoot S., McGuire A.T., Cohen K.W., Strong R.K., Hangartner L., Klein F., Diskin R., Scheid J.F., Sather D.N., Burton D.R., et al. Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog 2013, 9:e1003106.
64. McGuire A.T., Glenn J.A., Lippy A., Stamatatos L. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. J Virol 2014, 88:2645-2657.
65. Gorman J., Soto C., Yang M.M., Davenport T.M., Guttman M., Bailer R.T., Chambers M., Chuang G.Y., DeKosky B.J., Doria-Rose N.A., et al. Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol 2016, 23:81-90.
66. Jardine J.G., Kulp D.W., Havenar-Daughton C., Sarkar A., Briney B., Sok D., Sesterhenn F., Ereno-Orbea J., Kalyuzhniy O., Deresa I., et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science 2016, 351:1458-1463.
67. Streeck H., D'Souza M.P., Littman D.R., Crotty S. Harnessing CD4(+) T cell responses in HIV vaccine development. Nat Med 2013, 19:143-149.
68. Locci M., Havenar-Daughton C., Landais E., Wu J., Kroenke M.A., Arlehamn C.L., Su L.F., Cubas R., Davis M.M., Sette A., et al. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013, 39:758-769.
69. Havenar-Daughton C., Lindqvist M., Heit A., Wu J.E., Reiss S.M., Kendric K., Belanger S., Kasturi S.P., Landais E., Akondy R.S., et al. CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A 2016, 113:2702-2707.
70. Walker L.M., Sok D., Nishimura Y., Donau O., Sadjadpour R., Gautam R., Shingai M., Pejchal R., Ramos A., Simek M.D., et al. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque. Proc Natl Acad Sci U S A 2011, 108:20125-20129.
71. Shingai M., Donau O.K., Schmidt S.D., Gautam R., Plishka R.J., Buckler-White A., Sadjadpour R., Lee W.R., LaBranche C.C., Montefiori D.C., et al. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc Natl Acad Sci U S A 2012, 109:19769-19774.
72. AD8 infection. Sci Transl Med 2015, 7. 298ra120.
73. SF162P3N-infected macaques. J Virol 2016, 90:4017-4031.
74. Poulsen T.R., Jensen A., Haurum J.S., Andersen P.S. Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans. J Immunol 2011, 187:4229-4235.
75. Moody M.A., Zhang R., Walter E.B., Woods C.W., Ginsburg G.S., McClain M.T., Denny T.N., Chen X., Munshaw S., Marshall D.J., et al. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One 2011, 6:e25797.
76. Xiao X., Chen W., Feng Y., Zhu Z., Prabakaran P., Wang Y., Zhang M.Y., Longo N.S., Dimitrov D.S. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun 2009, 390:404-409.
77. Chen W., Prabakaran P., Zhu Z., Feng Y., Streaker E.D., Dimitrov D.S. Characterization of human IgG repertoires in an acute HIV-1 infection. Exp Mol Pathol 2012, 93:399-407.
78. Chen W., Streaker E.D., Russ D.E., Feng Y., Prabakaran P., Dimitrov D.S. Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: implications for mechanisms of immune evasion and design of vaccine immunogens. Biochem Biophys Res Commun 2012, 417:1164-1169.
79. Goo L., Chohan V., Nduati R., Overbaugh J. Early development of broadly neutralizing antibodies in HIV-1-infected infants. Nat Med 2014, 20:655-658.
80. Schatorje E.J., Driessen G.J., van Hout R.W., van der Burg M., de Vries E. Levels of somatic hypermutations in B cell receptors increase during childhood. Clin Exp Immunol 2014, 178:394-398.
81. Wu X., Zhang Z., Schramm C.A., Joyce M.G., Kwon Y.D., Zhou T., Sheng Z., Zhang B., O'Dell S., McKee K., et al. Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell 2015, 161:470-485.
82. Moore P.L., Gray E.S., Wibmer C.K., Bhiman J.N., Nonyane M., Sheward D.J., Hermanus T., Bajimaya S., Tumba N.L., Abrahams M.R., et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat Med 2012, 18:1688-1692.
83. Bhiman J.N., Anthony C., Doria-Rose N.A., Karimanzira O., Schramm C.A., Khoza T., Kitchin D., Botha G., Gorman J., Garrett N.J., et al. Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies. Nat Med 2015, 21:1332-1336.
84. Meffre E., Milili M., Blanco-Betancourt C., Antunes H., Nussenzweig M.C., Schiff C. Immunoglobulin heavy chain expression shapes the B cell receptor repertoire in human B cell development. J Clin Invest 2001, 108:879-886.
85. Wardemann H., Yurasov S., Schaefer A., Young J.W., Meffre E., Nussenzweig M.C. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377.
86. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., Robinson J., Scearce R.M., Plonk K., Staats H.F., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
87. Briney B.S., Willis J.R., Crowe J.E. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One 2012, 7:e36750.
88. Yu L., Guan Y. Immunologic basis for long HCDR3s in broadly neutralizing antibodies against HIV-1. Front Immunol 2014, 5:250.
89. Calarese D.A., Scanlan C.N., Zwick M.B., Deechongkit S., Mimura Y., Kunert R., Zhu P., Wormald M.R., Stanfield R.L., Roux K.H., et al. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300:2065-2071.
90. Mond J.J., Lees A., Snapper C.M. T cell-independent antigens type 2. Annu Rev Immunol 1995, 13:655-692.
91. Snapper C.M., Mond J.J. A model for induction of T cell-independent humoral immunity in response to polysaccharide antigens. J Immunol 1996, 157:2229-2233.
92. Reitter J.N., Means R.E., Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998, 4:679-684.
93. Wang L.X. Synthetic carbohydrate antigens for HIV vaccine design. Curr Opin Chem Biol 2013, 17:997-1005.
94. Hraber P., Seaman M.S., Bailer R.T., Mascola J.R., Montefiori D.C., Korber B.T. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014, 28:163-169.